The FDA issued an Emergency Use Authorization (EUA) to allow hydroxychloroquine sulfate and chloroquine phosphate products donated to the Strategic National Stockpile to be distributed and used for certain hospitalized patients with COVID-19
TOPIC: Chloroquine Phosphate Intended for Fish: FDA Letter to Stakeholders – Do Not Use as Treatment for COVID-19 in Humans
AUDIENCE: Consumer, Health Professional
ISSUE: The FDA’s Center for Veterinary Medicine has recently become aware that some consumers may mistake chloroquine phosphate used to treat disease in aquarium fish for FDA-approved drugs (used to treat malaria and certain other conditions in humans) that are being studied as a COVID-19 treatment for humans. Unfortunately, we have learned that one person in the United States has died after he and his wife reportedly took chloroquine used to treat their fish in an attempt to prevent COVID-19; his wife also became very ill.
Our primary concern during the COVID-19 pandemic is the imminent threat to the health of consumers who may take animal drugs thinking they are interchangeable with approved human drugs.
Healthcare business graph and Medical examination and businessman analyzing data and growth chart on blured background
PAHO has developed a searchable database that provides access to technical guidelines, scientific publications, and ongoing research protocols from the Americas and affected countries worldwide regarding the coronavirus disease (COVID-19) pandemic.
Recommendations and guidance from the Pan American Health Organization and the World Health Organization are also included, making it a useful platform of trusted information for decision and policy-making authorities, researchers, health professionals, and individuals.
FDA added hydroxyclhloroquine sulfate to category I under the interim policy on compounding bulk substances. Documents available at: https://www.fda.gov/media/94164/download
This document provides interim guidance on the management of the blood supply in response to the pandemic outbreak of coronavirus disease (COVID-19). It is intended for blood services, national health authorities, and others responsible for the provision of blood and blood components and integration of the blood system within the public health system. WHO will continue to update this guidance as new information becomes available.
